The results showed that PDIA3 was significantly and highly expressed in 16 cancers including bladder urothelial carcinoma, breast cancer, CESC, cholangiocarcinoma (CHOL), colon cancer, esophageal cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, renal clear cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, pheochromocytoma and paraganglioma, prostate adenocarcinoma, stomach adenocarcinoma, and uterine corpus endometrial carcinoma. Here, PDIA3 is linked to uterine corpus endometrial carcinoma.